Two Sigma Securities LLC Takes Position in Axsome Therapeutics, Inc. $AXSM

Two Sigma Securities LLC acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,708 shares of the company’s stock, valued at approximately $908,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Kemnay Advisory Services Inc. bought a new position in Axsome Therapeutics in the fourth quarter valued at about $31,000. Hollencrest Capital Management boosted its stake in shares of Axsome Therapeutics by 400.0% during the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after purchasing an additional 160 shares in the last quarter. Ameriflex Group Inc. bought a new stake in shares of Axsome Therapeutics during the fourth quarter worth about $37,000. Advisory Services Network LLC bought a new stake in shares of Axsome Therapeutics during the third quarter worth about $40,000. Finally, Farther Finance Advisors LLC increased its stake in shares of Axsome Therapeutics by 602.6% in the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock valued at $50,000 after buying an additional 235 shares during the period. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $198.52 on Tuesday. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. Axsome Therapeutics, Inc. has a twelve month low of $112.90 and a twelve month high of $260.19. The company has a fifty day moving average of $226.44 and a 200-day moving average of $206.99. The firm has a market capitalization of $10.40 billion, a P/E ratio of -52.94 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.The company had revenue of $218.38 million for the quarter, compared to the consensus estimate of $221.11 million. As a group, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.8 EPS for the current year.

Insiders Place Their Bets

In other news, Director Mark Coleman sold 643 shares of Axsome Therapeutics stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the transaction, the director directly owned 30,389 shares in the company, valued at $7,566,861. This trade represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Herriot Tabuteau sold 4,660 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $213.95, for a total value of $997,007.00. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,546,644.55. This represents a 39.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 183,229 shares of company stock worth $42,666,176 in the last quarter. Insiders own 20.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. UBS Group reiterated a “buy” rating on shares of Axsome Therapeutics in a report on Monday, August 24th. Wells Fargo & Company boosted their target price on shares of Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. BMO Capital Markets assumed coverage on shares of Axsome Therapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $310.00 price target for the company. Mizuho lifted their price target on shares of Axsome Therapeutics from $306.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Finally, Guggenheim lifted their price target on shares of Axsome Therapeutics from $260.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.60.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.